Recent

% | $
Quotes you view appear here for quick access.

Pfizer Inc. Message Board

  • riskybiz1111 riskybiz1111 May 20, 2013 8:14 AM Flag

    Lipitor Alert! What Do Medivation And AtheroNova Have In Common?

    Medivation Inc. (NASDAQ: MDVN) is a classic Wall Street success story. Founded by a group of experienced professionals, the company acquired early stage pharmaceuticals and medical devices that had promising clinical, intellectual property and commercial prospects and grew from just $5.00 per share in 2010 to nearly $60.00 per share three years later. The majority of this growth happened in late 2011/early 2012, when the stock appreciated nearly 500% after successful clinical trials unlocked significant value in its product pipeline. [1]
    Behind the scenes of this success, was biotech investment fund manager Fred Knoll, via his firm Knoll Capital Management, as a key investor. The fund began building a stake in the company in early 2006, where it acquired about $7.2 million worth of stock, according to regulatory filings. By the same time in 2007, the fund had increased its share ownership and the $66 million position became the largest in its portfolio. And, according to the fund’s most recent regulatory filings, the stake is now worth more than $130 million today. [2]
    Taking a New Biotech Under the Wing
    Fred Knoll may be interested in another unique biotech play, based on his involvement in a fund called Europa International Inc. With Knoll Capital Management as an advisor, Europa International acquired a shell holding company that reverse merged with a biotech company called AtheroNova Inc. (OTCQB: AHRO) to take it public. The stock has since been quietly trading – much like Medivation – whilst pursuing clinical trials. If Mr. Knoll is right about this company, as he was with Medivation, the stock could see significant upside from these levels. [2]
    AtheroNova’s most advanced candidate, AHRO-001, is a proprietary compound administered via tablet that dissolves plaque within arterial walls, through a process known as delipidization, and then safely remove it from the body using a natural metabolic process. With the s

 
PFE
34.53+0.37(+1.08%)Mar 27 4:02 PMEDT